公开(公告)号：US11066472B2

公开(公告)日：2021-07-20

申请号：US16230356

申请日：2018-12-21

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky

IPC: A61P9/10 ,  A61P3/06 ,  A61K39/395 ,  C07K16/28 ,  A61P9/04 ,  C12N15/113 ,  C07H21/02 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US10227406B2

公开(公告)日：2019-03-12

申请号：US14899551

申请日：2014-06-25

Applicant: AMGEN INC.

Inventor： Peter Coward ,  Steven A. Moore, Jr. ,  Shi-Yuan Meng ,  Mei-Mei Tsai ,  Chadwick Terence King ,  Aaron Avraham Nazarian

IPC: C07K16/28

Abstract: This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.

公开(公告)号：US20210163601A1

公开(公告)日：2021-06-03

申请号：US16987237

申请日：2020-08-06

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  A61P9/10 ,  A61P9/04 ,  C12N15/113 ,  C07H21/02 ,  A61P3/06 ,  A61K39/395 ,  A61K45/06

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20190248902A1

公开(公告)日：2019-08-15

申请号：US16230356

申请日：2018-12-21

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  C07H21/02 ,  A61K39/395 ,  A61P9/10 ,  A61P9/04 ,  A61K45/06 ,  C12N15/113

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1138

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20250051457A1

公开(公告)日：2025-02-13

申请号：US18770259

申请日：2024-07-11

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P3/06 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C12N15/113

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20170088620A1

公开(公告)日：2017-03-30

申请号：US15279162

申请日：2016-09-28

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mintung Chang

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1138

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.